Internal Medicine, Hematology & Oncology · Orlando, FL
NPI
1205934288
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
922 Lucerne Ter
Orlando, FL, 32806
Phone (407) 426-8660
Groups this clinician bills Medicare through
Medicare paid, 2024
$176K
16,431 services
Medicare patients, 2024
259
Average age 75
Drug cost, 2024
$9.2M
1,634 prescriptions
Company payments, 2025
$3,423
From 45 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas J Katta was code 85025 (blood count), 848 times for 196 patients. In total Thomas J Katta billed 16,431 services in 46 codes, and Medicare paid $176K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 85025 Blood Count | Office | 848 | 196 | $7.58 | $6,430 |
| 36415 Venipuncture Blood Collection | Office | 848 | 196 | $8.64 | $7,327 |
| 99214 Office E&M - Established | Office | 783 | 197 | $90.20 | $71K |
| 96372 Injection Administration | Office | 163 | 19 | $10.80 | $1,760 |
| 99232 Hospital E&M - Subsequent | Facility | 101 | 28 | $61.01 | $6,162 |
| 99205 Office E&M - New | Office | 40 | 40 | $153.47 | $6,139 |
| 99233 Hospital E&M - Subsequent | Facility | 39 | 14 | $91.16 | $3,555 |
| 99213 Office E&M - Established | Office | 27 | 15 | $70.38 | $1,900 |
By year: 2022 $388K for 15,192 services; 2023 $237K for 19,516 services; 2024 $176K for 16,431 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 848 | 196 | $8.64 | $7,327 |
| 85025 Blood Count | 848 | 196 | $7.58 | $6,430 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas J Katta prescribed most often to Medicare patients was Retacrit (Epoetin Alfa-Epbx), with 128 prescriptions and refills. In total Thomas J Katta wrote 1,634 Medicare prescriptions that cost $9.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Retacrit Epoetin Alfa-Epbx | 128 | 128 | 24 | $142K |
| Hydroxyurea Generic | 93 | 169 | 19 | $3,268 |
| Letrozole Generic | 91 | 258 | 28 | $2,059 |
| Imbruvica Ibrutinib | 85 | 85 | Under 11 | $1.3M |
| Ondansetron Hcl Generic | 69 | 70 | 24 | $2,122 |
| Lenalidomide Generic | 67 | 67 | Under 11 | $1.1M |
| Prednisone Generic | 50 | 53 | 12 | $189 |
| Dexamethasone Generic | 49 | 52 | 21 | $885 |
| Keytruda Pembrolizumab | 46 | 46 | Under 11 | $505K |
| Xtandi Enzalutamide | 46 | 46 | Under 11 | $621K |
| Eliquis Apixaban | 45 | 59 | 12 | $33K |
| Revlimid Lenalidomide | 42 | 42 | Under 11 | $770K |
| Warfarin Sodium Generic | 34 | 94 | Under 11 | $413 |
| Procrit Epoetin Alfa | 33 | 33 | Under 11 | $77K |
| Jakafi Ruxolitinib Phosphate | 25 | 25 | Under 11 | $438K |
Brand drugs: 847 claims; generic drugs: 787 claims; opioid claims: 32.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas J Katta $3,423 ($3,423 in general payments such as food, travel and fees) from 45 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $468.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 16 | $468 |
| Celgene Corporation BMY | 12 | $244 |
| Eisai Inc. 4523.T | 9 | $198 |
| Novartis Pharmaceuticals Corporation NVS | 10 | $194 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 8 | $178 |
| Merck Sharp & Dohme LLC MRK | 7 | $160 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 6 | $124 |
| Incyte Corporation INCY | 6 | $124 |
| Pfizer Inc. PFE | 6 | $116 |
| Array Biopharma Inc PFE | 5 | $104 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.